King's College London

Research portal

Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial

Research output: Contribution to journalArticle

Standard

Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO) : a prospective, randomised placebo-controlled feasibility trial. / Merrick, Blair; Robinson, Emily; Bunce, Catey; Allen, Liz; Bisnauthsing, Karen; Izundu, Chi Chi; Bell, Jordana; Amos, Gregory; Shankar-Hari, Manu; Goodman, Anna; Shawcross, Debbie L; Goldenberg, Simon D.

In: BMJ Open, Vol. 10, No. 5, e038847, 25.05.2020, p. e038847.

Research output: Contribution to journalArticle

Harvard

Merrick, B, Robinson, E, Bunce, C, Allen, L, Bisnauthsing, K, Izundu, CC, Bell, J, Amos, G, Shankar-Hari, M, Goodman, A, Shawcross, DL & Goldenberg, SD 2020, 'Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial', BMJ Open, vol. 10, no. 5, e038847, pp. e038847. https://doi.org/10.1136/bmjopen-2020-038847

APA

Merrick, B., Robinson, E., Bunce, C., Allen, L., Bisnauthsing, K., Izundu, C. C., ... Goldenberg, S. D. (2020). Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. BMJ Open, 10(5), e038847. [e038847]. https://doi.org/10.1136/bmjopen-2020-038847

Vancouver

Merrick B, Robinson E, Bunce C, Allen L, Bisnauthsing K, Izundu CC et al. Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. BMJ Open. 2020 May 25;10(5):e038847. e038847. https://doi.org/10.1136/bmjopen-2020-038847

Author

Merrick, Blair ; Robinson, Emily ; Bunce, Catey ; Allen, Liz ; Bisnauthsing, Karen ; Izundu, Chi Chi ; Bell, Jordana ; Amos, Gregory ; Shankar-Hari, Manu ; Goodman, Anna ; Shawcross, Debbie L ; Goldenberg, Simon D. / Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO) : a prospective, randomised placebo-controlled feasibility trial. In: BMJ Open. 2020 ; Vol. 10, No. 5. pp. e038847.

Bibtex Download

@article{92bfb51ed0e64d4aa9598082306769e3,
title = "Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial",
abstract = "INTRODUCTION: Antimicrobial resistance is rising, largely due to the indiscriminate use of antimicrobials. The human gut is the largest reservoir of antibiotic resistant bacteria (ARB). Individuals colonised with ARB have the potential to spread these organisms both in the community and hospital settings. Infections with ARB such as extended spectrum beta-lactamase producing enterobacteriales (ESBL-E) and carbapenemase producing enterobacteriales (CPE) are more difficult to treat and are associated with an increased morbidity and mortality. Presently, there is no effective decolonisation strategy for these ARB. Faecal microbiota transplant (FMT) has emerged as a potential strategy for decolonisation of ARB from the human gut, however there is significant uncertainty about the feasibility, effectiveness and safety of using this approach.METHODS AND ANALYSIS: Prospective, randomised, patient-blinded, placebo-controlled feasibility trial of FMT to eradicate gastrointestinal carriage of ARB. Eighty patients with a recent history of invasive infection secondary to ESBL-E or CPE and persistent gastrointestinal carriage will be randomised 1:1 to receive encapsulated FMT or placebo. The primary outcome measure is consent rate (as a proportion of patients who fulfil inclusion/exclusion criteria); this will be used to determine if a substantive trial is feasible. Participants will be followed up at 1 week, 1 month, 3 months and 6 months and monitored for adverse events as well as gastrointestinal carriage rates of ARB after intervention.ETHICS AND DISSEMINATION: Research ethics approval was obtained by London-City and East Research Ethics Committee (ref 20/LO/0117). Trial results will be published in a peer-reviewed journal and presented at international conferences.TRIAL REGISTRATION NUMBER: ISRCTN registration number 34 467 677 and EudraCT number 2019-001618-41.",
keywords = "bacteriology, infection control, microbiology",
author = "Blair Merrick and Emily Robinson and Catey Bunce and Liz Allen and Karen Bisnauthsing and Izundu, {Chi Chi} and Jordana Bell and Gregory Amos and Manu Shankar-Hari and Anna Goodman and Shawcross, {Debbie L} and Goldenberg, {Simon D}",
note = "{\circledC} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.",
year = "2020",
month = "5",
day = "25",
doi = "10.1136/bmjopen-2020-038847",
language = "English",
volume = "10",
pages = "e038847",
journal = "BMJ Open",
issn = "2044-6055",
number = "5",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO)

T2 - a prospective, randomised placebo-controlled feasibility trial

AU - Merrick, Blair

AU - Robinson, Emily

AU - Bunce, Catey

AU - Allen, Liz

AU - Bisnauthsing, Karen

AU - Izundu, Chi Chi

AU - Bell, Jordana

AU - Amos, Gregory

AU - Shankar-Hari, Manu

AU - Goodman, Anna

AU - Shawcross, Debbie L

AU - Goldenberg, Simon D

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

PY - 2020/5/25

Y1 - 2020/5/25

N2 - INTRODUCTION: Antimicrobial resistance is rising, largely due to the indiscriminate use of antimicrobials. The human gut is the largest reservoir of antibiotic resistant bacteria (ARB). Individuals colonised with ARB have the potential to spread these organisms both in the community and hospital settings. Infections with ARB such as extended spectrum beta-lactamase producing enterobacteriales (ESBL-E) and carbapenemase producing enterobacteriales (CPE) are more difficult to treat and are associated with an increased morbidity and mortality. Presently, there is no effective decolonisation strategy for these ARB. Faecal microbiota transplant (FMT) has emerged as a potential strategy for decolonisation of ARB from the human gut, however there is significant uncertainty about the feasibility, effectiveness and safety of using this approach.METHODS AND ANALYSIS: Prospective, randomised, patient-blinded, placebo-controlled feasibility trial of FMT to eradicate gastrointestinal carriage of ARB. Eighty patients with a recent history of invasive infection secondary to ESBL-E or CPE and persistent gastrointestinal carriage will be randomised 1:1 to receive encapsulated FMT or placebo. The primary outcome measure is consent rate (as a proportion of patients who fulfil inclusion/exclusion criteria); this will be used to determine if a substantive trial is feasible. Participants will be followed up at 1 week, 1 month, 3 months and 6 months and monitored for adverse events as well as gastrointestinal carriage rates of ARB after intervention.ETHICS AND DISSEMINATION: Research ethics approval was obtained by London-City and East Research Ethics Committee (ref 20/LO/0117). Trial results will be published in a peer-reviewed journal and presented at international conferences.TRIAL REGISTRATION NUMBER: ISRCTN registration number 34 467 677 and EudraCT number 2019-001618-41.

AB - INTRODUCTION: Antimicrobial resistance is rising, largely due to the indiscriminate use of antimicrobials. The human gut is the largest reservoir of antibiotic resistant bacteria (ARB). Individuals colonised with ARB have the potential to spread these organisms both in the community and hospital settings. Infections with ARB such as extended spectrum beta-lactamase producing enterobacteriales (ESBL-E) and carbapenemase producing enterobacteriales (CPE) are more difficult to treat and are associated with an increased morbidity and mortality. Presently, there is no effective decolonisation strategy for these ARB. Faecal microbiota transplant (FMT) has emerged as a potential strategy for decolonisation of ARB from the human gut, however there is significant uncertainty about the feasibility, effectiveness and safety of using this approach.METHODS AND ANALYSIS: Prospective, randomised, patient-blinded, placebo-controlled feasibility trial of FMT to eradicate gastrointestinal carriage of ARB. Eighty patients with a recent history of invasive infection secondary to ESBL-E or CPE and persistent gastrointestinal carriage will be randomised 1:1 to receive encapsulated FMT or placebo. The primary outcome measure is consent rate (as a proportion of patients who fulfil inclusion/exclusion criteria); this will be used to determine if a substantive trial is feasible. Participants will be followed up at 1 week, 1 month, 3 months and 6 months and monitored for adverse events as well as gastrointestinal carriage rates of ARB after intervention.ETHICS AND DISSEMINATION: Research ethics approval was obtained by London-City and East Research Ethics Committee (ref 20/LO/0117). Trial results will be published in a peer-reviewed journal and presented at international conferences.TRIAL REGISTRATION NUMBER: ISRCTN registration number 34 467 677 and EudraCT number 2019-001618-41.

KW - bacteriology

KW - infection control

KW - microbiology

UR - http://www.scopus.com/inward/record.url?scp=85085412522&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2020-038847

DO - 10.1136/bmjopen-2020-038847

M3 - Article

C2 - 32457083

VL - 10

SP - e038847

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 5

M1 - e038847

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454